Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Companies Ink siRNA Deals
by Lisa M. Jarvis
April 5, 2010
| A version of this story appeared in
Volume 88, Issue 14
More companies have plans to develop small-interfering-RNA-based drugs. Dicerna Pharmaceuticals and Ipsen will work together to improve the delivery of siRNA. The goal is to make novel conjugates of Dicerna's dicer-substrate siRNA molecules and Ipsen's peptide-targeting vectors to develop therapeutics for oncology and endocrinology. In a separate deal, Silence Therapeutics and Dainippon Sumitomo Pharma have expanded an siRNA delivery pact they initiated in August. The new deal adds to the number of disease targets that Dainippon can access through Silence's siRNA stabilization technology and its lipid delivery technology.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter